ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0425

High Density Lipoprotein Dysfunction in Juvenile Idiopathic Arthritis as Compared to Children without Rheumatologic Disease

Tahnee Spoden1, Samira Nazzar Romero2, Deborah McCurdy3, Alice Hoftman4, Sangmee Bae5, Jennifer Wang4, Ani Shahbazian4 and Christina Charles-Schoeman6, 1UCLA, Los Angeles, CA, 2Nemours Children's Health, Orlando, 3UCLA Medical Center, Los Angeles, CA, 4UCLA, Los Angeles, 5UCLA Rheumatology, Los Angeles, CA, 6UCLA Medical Center, Santa Monica, CA

Meeting: ACR Convergence 2025

Keywords: Atherosclerosis, Disease Activity, Juvenile idiopathic arthritis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0387–0429) Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Cardiovascular disease remains the leading cause of mortality in patients with Rheumatoid Arthritis (RA). Normally, high density lipoprotein (HDL) acts in a cardioprotective capacity through various anti-inflammatory and anti-oxidative functions. Research has shown that the antiinflammatory capacity of HDL is impaired in states of chronic inflammation, such as RA. Abnormal lipid profiles have been described in patients with JIA, however, qualitative studies on HDL in this population are lacking. We aim to investigate if the antiinflammatory function of HDL is impaired in JIA patients as compared to healthy controls. We also aim to investigate if HDL dysfunction correlates with JIA subtype and disease activity.

Methods: We performed a cross-sectional study on 30 patients with JIA and 15 controls between 9 and 17 years of age. Disease activity was assessed based on the juvenile arthritis disease activity score (JADAS-10) and the childhood health assessment questionnaire (CHAQ). HDL’s antiinflammatory function (HII) was measured using a cell-free assay assessing the ability of the patient’s HDL to inhibit oxidation of low-density lipoprotein. Circulating oxidized biproducts of arachidonic and linoleic acid were measured by liquid chromatography-electrospray ionization, tandem mass spectroscopy. HDL-associated apoprotein A-1 (ApoA1) levels were measured by sandwich ELISA. Levels and activity of HDL associated antioxidant enzymes PON-1 (paraoxonase, arylesterase and lactonase) were quantified using spectrophotometry.

Results: Total HDL and total cholesterol were not significantly different between cases and controls. Joint count in the 22 patients with poly-JIA was higher than the 8 patients with other subtypes of JIA (63% ERA, 38% psoriatic JIA) [mean (s.d.)] (4.5 (4.3), 1.1 (1), p=0.002). ESR was significantly higher in the poly JIA group (17 (19), 6 (6), p=0.022). The HII was higher JIA subtypes associated with spondyloarthropathy as compared to poly-JIA and controls (p=0.0447, p=0.0179). HDL concentration correlated significantly with the HII (rs= -0.63, p= 0.0003) in all JIA patients and correlated with disease activity. Several circulating bioactive lipid mediators were significantly higher in JIA patients compared with controls with 9HODE,15HODE and 11HETE showing positive correlation with the HII (rs = 0.36-0.44, p= 0.05-0.02). Arylesterase and Lactonase activity negatively correlated with joint count (rs= -0.41, p=0.026; rs=-0.38, p=0.041) and ESR (rs=-0.40, p=0.027; rs=-0.41, p= 0.023) respectively in all JIA patients.

Conclusion: This pilot study demonstrates that chronic inflammation in patients with JIA may contribute to HDL dysfunction, particularly in patients with axial involvement. Larger cohort studies are needed to further characterize patients with axial disease as well as aide in our understanding of how PON-1 changes over time in children with chronic inflammation.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: T. Spoden: None; S. Nazzar Romero: None; D. McCurdy: None; A. Hoftman: None; S. Bae: None; J. Wang: None; A. Shahbazian: None; C. Charles-Schoeman: AbbVie/Abbott, 2, 5, Alexion, 5, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, 5, CSL Behring, 5, Galapagos, 2, Immunovant, 2, Janssen, 5, Octapharma, 2, 5, Pfizer, 2, 5, Priovant, 5, Recludix, 2, Sana Biotechnology, 2.

To cite this abstract in AMA style:

Spoden T, Nazzar Romero S, McCurdy D, Hoftman A, Bae S, Wang J, Shahbazian A, Charles-Schoeman C. High Density Lipoprotein Dysfunction in Juvenile Idiopathic Arthritis as Compared to Children without Rheumatologic Disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/high-density-lipoprotein-dysfunction-in-juvenile-idiopathic-arthritis-as-compared-to-children-without-rheumatologic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-density-lipoprotein-dysfunction-in-juvenile-idiopathic-arthritis-as-compared-to-children-without-rheumatologic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology